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Background: Exactly assessing tumor response to different dose of chemotherapy would help to tailor therapy for
individual patients. This study was to determine the feasibility of dynamic contrast-enhanced ultrasound (CEUS) in
the evaluation of tumor vascular response to different dose cisplatin.
Methods: MCF-7 breast cancer bearing mice were treated with different dose of cisplatin in group B (1 mg/kg) and
group C (3 mg/kg). A control group A was given with saline. Sequential CEUS was performed on days 0, 3 and 7 of
the treatment, in which time-signal intensity curves were obtained from the intratumoral and depth-matched liver
parenchyma. Peak enhancement (PE), area under the curve of wash-in (WiAUC), wash-in rate (WiR) and wash-in
perfusion index (WiPI) were calculated from perfusion time-intensity curves and normalized with respect to the
adjacent liver parenchyma. Histopathological analysis was conducted to evaluate tumor cell density and microvascular
density (MVD).
Results: Significant decreases in tumor normalized perfusion parameters were observed on day 3 in the high dose
group and on day 7 in the low dose group. On day 7, nPE, nWiAUC, and nWiPI significantly decreased in group C and
group B as compared with group A (P < 0.05), and further decreased in group C as compared with group B (P < 0.05).
Significant decreases of tumor cell density and MVD were seen in treated group (group B and C) compared to control
group (P < 0.05) and further decrease in group C compared to group B (P < 0.05).
Conclusions: Dynamic CEUS for quantification of tumor perfusion could be used to evaluate tumor vascular response
to different dose of chemotherapy.
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The cytotoxic chemotherapeutics have been used for
systemic cancer therapy for half a century. On the basis
of the concept that a given dose of an antineoplastic
compound would destroy a certain fraction of tumor
cells, the efficiency of tumor chemotherapy, to a great
extent, is dependent on the dosage of drugs and higher
doses are supposed to be more effective. Therefore,
high-dose chemotherapy with autologous bone-marrow* Correspondence: anhuali@hotmail.com; zjh96421@hotmail.com
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unless otherwise stated.transplants has been widely used in the treatment of rare
types of cancer, unresponsive cancer and cancer relapse
[1,2]. However, high-dose chemotherapy in solid tumor
in order to boost the effect of anti-cancer therapy is al-
ways under controversy. The studies of Leonard RC and
Roche H et al. showed that high-dose chemotherapy
with autologous bone-marrow stem-cell transplants had
not improved the overall survival and disease free sur-
vival as expected, when used for patients with metastatic
breast cancer [3,4]. Moreover, this approach is also very
expensive and highly toxic. Thus, exactly assessing
tumor response to different dose of chemotherapy is ur-
gently needed, which could not only be helpful to tailorhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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medical resource.
Ultrasound is an attractive imaging technique for as-
sessment tumor response to treatment because it can be
repeated without exposing the patient or animal to any
risk of radiation. Ultrasound imaging systems are also
relatively inexpensive and mobile when compared other
imaging modalities, a particular benefit for animal stud-
ies. The use of microbubble-based contrast agents com-
bined with contrast specific imaging modalities has
considerably improved the visualization of microvascular
perfusion that is undetectable with traditional Doppler
techniques. Noninvasive contrast-enhanced ultrasound
imaging offers the major advantages of evaluating tumor
perfusion in real time and without any risk of ionizing
radiation when compared to other methods used to as-
sess tumor perfusion [5]. Numerous studies have used
dynamic contrast-enhanced ultrasound to assess vascu-
lar changes associated with response to antiangiogenic
therapy [6-9]. Recently, the treatment effect of cytotoxic
chemotherapy was evaluated with the use of dynamic
contrast-enhanced ultrasound in both animal [10,11]
and clinical studies [12,13] and preliminary results were
promising.
The purpose of our study was to measure the dose–
response relationship in cisplatin-treated breast tumor xe-
nografts by using dynamic contrast-enhanced ultrasound.
Methods
Animal preparation
This study was approved by the Committee on the
Ethics of Animal Experiments of the Sun Yat-Sen
University under the guidelines of the National Institutes
of Health for the care of laboratory animals. Human
breast cancer cell line MCF-7 was obtained from State
Key Laboratory of Oncology in Southern China. MCF-7
cells were grown in DMEM culture medium (Hyclone
Co., UT, USA) supplemented with 10% fetal bovine
serum (Gibco, Grand Island, NY, USA), penicillin (50U/
ml), and streptomycin (50 μg/ml) at 37°C in a humidi-
fied 5% CO2 atmosphere. For inoculation, approximately
5 × 107 MCF-7 cells suspended in phosphate-buffered
saline were injected subcutaneously into the right flanks
of 8-week old BALB/c female nude mice.
Experimental design
A total of 70 mice were used for the experiment and the
mice were randomly divided into 3 groups with group A
(n = 26) as control subjects and groups B and C (n = 22
on each) as treatment subjects. Cytotoxic chemotherapy
agent, cisplatin (Mayne Pharma Pty Ltd, Salisbury,
Australia) diluted in sterile saline was administered by
intraperitoneal injection once daily at the dose of 1 mg/
kg for group B and 3 mg/kg for group C 12 days posttumor cell implantation. The mice in control group
(group A) received vehicle control medium (sterile sa-
line) with same timing and dosing schedule used for
treatment group. The fluid volume of intraperitoneal in-
jection given for the treatment and control tumors was
10 μl per gram of body weight. The time point for the
first dose given was referred to as day 0. Ultrasound im-
aging was performed at days 0, 3 and 7 before each dos-
ing. On day 0, 5 mice randomly chosen from the control
group were sacrificed and tumors were excised for histo-
pathologic analysis. On day 3, histopathologic analysis
were performed in 9 mice of group A, 8 mice of group B
and 8 mice of group C, respectively. On day 7, the
remaining mice (11 mice in group A, 13 mice in group
B and 14 mice in group C) were sacrificed and tumors
were excised for histopathologic analysis after ultrasound
imaging.US imaging protocol
One radiologist (with 8 years experience) who was
blinded to treatment groups performed contrast-
enhanced US for all groups on days 0, 3 and 7 before
dosing of cisplatin. Ultrasound imaging with contrast
pulse sequence (CPS) technique [14,15] were obtained
using an Acuson Sequoia 512 (Siemens, Mountain View,
CA) ultrasound unit with a linear array transducer (7.0
~ 14.0 MHz). Coupling gel with a gel pad was placed on
the skin for stand-off scanning. CPS imaging mode was
used for evaluation of tumor perfusion with mechanical
index of 0.25, frame rate of 5Hz, dynamic range of
78 dB, and imaging depth of 3 cm. These settings were
adjusted at the beginning and maintained constant dur-
ing all of the experiments.
For the ultrasound imaging studies, each mouse was
anesthetized by intraperitoneal injection of pentobarbital
sodium (75 mg/kg, Sigma, St. Louis, MO). Two of the
70 mice (one from group A on day 3 and one from
group B from day 7) died during the anesthesia and were
excluded from analysis. A heating pad was used to avoid
reductions in body temperature which may affect mice
blood circulation.
Initial US imaging was performed with a hand-held 7-
to 14-MHz probe to find a transverse image plane con-
taining the tumor at its maximum cross section and a
large portion of the right lobe of the liver parenchyma.
Before contrast agent injection, the greatest longitudinal,
transverse, and anteroposterior dimensions of tumors
were measured in fundamental grayscale imaging.
Tumor volume was calculated using the formula for a
prolate ellipsoid: volume = π/6 × length × width × depth.
The maximum cross-section plane of the tumor was im-
aged with the transducer held manually in this position
throughout the examination.
Chen et al. BMC Cancer  (2015) 15:136 Page 3 of 9Lipid-based ultrasound contrast agent SonoVue
(Bracco, Milan, Italy) dissolved with physiologic saline to
5 ml was used in this study. SonoVue was administered
as a bolus (0.1 ml/20 g) into the retroorbital vein using a
27-gauge needle. The bolus injection was performed by
one radiologist (W.Z., with 6 years experience in small
animals study) within 1 sec for all animals to minimize
variations of injection technique. Imaging was recorded
on cine clips starting just before the contrast agent injec-
tion and continuing for 60 sec.
Functional study
Off-line evaluation of the perfusion curves was per-
formed by one investigator (Y.C.) who was blind to the
treatment information. The clips were downloaded in a
Digital Imaging and Communications in Medicine for-
mat for offline processing with the use of SonoTumor
software (Bracco Research SA, Geneva, Switzerland)
using a bolus kinetic model. Initially, a region of interest
(ROI) that drawn along the margin of the tumor and a
ROI at matched depth in the region of the right lobe of
the liver parenchyma were selected by one investigator
who was blind to the treatment information. The ana-
lysis applies first linearization at the pixel level to revert
the effects of “log” compression in the ultrasound sys-
tem. Results obtained from the selected ROI represented
an approximately linear depiction of the backscattered
intensity. The average of the linearized intensities of all
the pixels in the ROI was calculated to produce a time-
signal intensity curve, where the signal intensity is theor-
etically linked to the concentration of the microbubbles
in the blood circulation [16,17], and a mathematic equa-
tion model was used to fit the contrast uptake time–
intensity curve.
Four tumor perfusion parameters, including peak en-
hancement (PE), area under the curve of wash-in
(WiAUC), wash-in rate (WiR) and wash-in perfusion
index (WiPI) were calculated and normalized to the depth-
matched liver parenchyma (Perfusion parameters tumor/
Perfusion parameters liver). The results were noted as nPE,
nWiAUC, nWiR and nWiPI (n = normalized). Quality of
fit (QOF) was used to test the fit between the raw data
and the fitted mathematic model. The wash-in phase of
contrast was defined between the time of onset of contrast
inflow and the time of peak enhancement.
Histology
Tumors were removed and fixed in 10% buffered forma-
lin before paraffin processing. The tumor specimens
were sectioned at the largest cross sections in four-μm-
thick and stained with hemotoxylin and eosin stain
(H&E) to assess the cell morphology changes. Endothe-
lial cell (CD34) density (microvascular density, MVD)
was assessed by immunohistochemical method Antigen-retrieval procedure using citrate acid (pH of 6.0) was
performed. Primary antibody incubation was performed
using a rat antimouse CD34 antibody (clone MEC14.7,
Abcam, UK) at 1:100 dilution overnight at 4°C. After
rinsing with phosphate buffered saline (PBS), a second-
ary rabbit antirat antibody (Zhongshan Goldenbridge
Biology, Beijing, China) was added and diaminobenzi-
dine (DAB) for color development.
Regions with the highest tumor cell density in H&E
stained sections were located by scanning the tissue sec-
tions under × 40-power microscope and ten different
fields within the regions of highest tumor cell density
were randomly chosen at × 400. The histology images of
each 400× field were saved in the computer for the
measurement of tumor cell density. Image pro plus soft-
ware (image pro-plus 6.0; Media Cybernetics, Sliver
Spring, MD, USA) was used to calculate the number of
nuclei of each histology image. Data were averaged over
ten fields for statistical analysis.
The measurements of MVD by counting the CD34-
stained vessels under light microscopy were performed
independently by two experienced observers, who were
blinded to the tumor treatment and ultrasound findings
according to a well established method by Weidner et al.
[18]. After the “hot spots” were identified under × 40-
power microscope, three fields were randomly chosen
and the numbers of individual brown-stained cells were
counted at × 400 powers for MVD measurements. The
average of the two observers’ results was used for statis-
tical analysis.
Statistical analysis
All analyses were performed using SPSS version 16.0
(SPSS, Inc, Chicago, IL). The Kolmogorov-Smirnov test
was applied to evaluate normal distribution. The Levene
test was applied to evaluate the homogeneity of variance.
One-way analysis of variance (ANOVA) tests were used
to determine the significant differences of tumor vol-
ume, perfusion parameters, tumor cell density and MVD
among the three groups. Confirming that there were sig-
nificant differences among the three groups, the post
hoc Bonferroni corrected t test was performed for mul-
tiple comparisons to determine difference between indi-
vidual groups. The Pearson correlation test was used to
determine the relationship between perfusion parame-
ters and histopathological changes. A P value of < 0.05
or less was considered statistically significant.
Results
Effects of cisplatin treatment on tumor growth
All mice could tolerate 7 days treatment and no obvi-
ously adverse effect was observed in the mice treated
with low-dose cisplatin, however, treatment with high-
dose cisplatin caused obviously adverse effects on the
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crease of activity. There was no significant difference in
tumor volume among the three groups on days 0 and 3
(P was 0.404 and 0.258, respectively). On day 7, one-way
analyses showed significant difference in tumor volume
among the three groups (P = 0.001). Tumor volume of
group B and C was significantly lower than that of group
A (P was 0.029 and 0.001, respectively), however, there
was no significant difference in tumor volume between
the two treated groups (P = 0.691) (Figure 1).
Different dose of cisplatin treatment on tumor perfusion
parameters
The raw data of bolus kinetics were well fitted to the
mathematical model that the software of SonoTumor
used. The mean QOF of the three groups was 0.96 ± 0.02.
In the control group (group A), CEUS demonstrated
that only nPE significantly increased on day 7 as com-
pared with day 0 (P = 0.023), while the other three perfu-
sion parameters did not significantly changed on day 3
and 7 as compared with day 0 (P > 0.05) . In the low-
dose group (group B), CEUS demonstrated that all four
normalized perfusion parameters significantly decreased
on day 7 as compared with day 0 (P < 0.05), while there
were no significant changes in the perfusion parameters
on day 3 as compared with day 0 (P > 0.05). In the high-
dose group (group C), CEUS demonstrated that all four
normalized perfusion parameters significantly decreased
as early as 3 days after cisplatin therapy and remained
low throughout the entire observation period as com-
pared with day 0 (P < 0.05).
There were no significant differences in 4 norma-
lized perfusion parameters (i.e., nPE, nWiAUC, nWiRFigure 1 Changes of tumor volume after treatment with
different dose cisplatin. Tumor volume of group B and C was
significantly lower than that of group A on day 7 (* = P < 0.05) while
there were no significant differences in tumor volume among the
three groups on days 0, and 3 (* = P > 0.05). Group A, control
tumors; Group B, tumors treated with 1 mg/kg cisplatin; Group C,
tumors treated with 3 mg/kg cisplatin.and nWiPI) among the three groups before treatment
(P > 0.05). On day 3, nPE, nWiAUC and nWiPI signifi-
cantly decreased in group C as compared with group
A (P < 0.05) and only nWiPI significantly decreased in
group C as compared with group B (P = 0.025), while there
was no significant difference in perfusion parameters be-
tween group B and group A (P > 0.05). On day 7, nPE,
nWiAUC, nWiR and nWiPI significantly decreased in
group C as compared with group A (P < 0.05), nPE,
nWiAUC and nWiPI significantly decreased in group C as
compared with group B (P < 0.05), and nPE, nWiAUC and
nWiPI significantly decreased in group B as compared
with group A (P < 0.05) (Figure 2).
Histopathological finding in tumors
Typical control (group A), low-dose (group B) and high-
dose (group C) cisplatin-treated MCF-7 tumor sections
stained by H&E are shown in Figure 3.
In the group A, tumor cell density remained stable on
day 3 and 7 as compared with day 0 (P > 0.05). In the
group B, tumor cell density significantly decreased on
day 3 and 7 as compared with day 0 (P < 0 .001), while
there was no significant difference between day 3 and 7
(P = 1.0). In the group C, tumor cell density significantly
decreased on day 3 and 7 as compared with day 0 (P < 0
.001), and further decreased on day 7 as compared with
day 3 (P = 0 .008).
On day 3 and 7, tumor cell density significantly de-
creased in treated tumors (groups B and C) with respect
to the control tumors (group A, P < 0 .001) and cell
density significantly decreased in group C as compared
with group B (P < 0 .001).
In the group A, MVD remained stable on day 3 and 7
as compared with day 0 (P > 0.05). In the group B, MVD
significantly decreased on day 7 as compared with day 0
and 3(P < 0 .001), while there was no significant differ-
ence between day 0 and 3(P = 0.437). In the group C,
MVD significantly decreased on day 3 and 7 as com-
pared with day 0 (P < 0 .001), while there was no signifi-
cant difference between day 3 and 7 (P = 0.125).
On day 3, MVD significantly decreased in group C as
compared with group A and B (P < 0 .001), while there
was no significant difference in MVD between group A
and B (P = 0.112). On day 7, MVD significantly decreased
in group C as compared with group A and B (P < 0 .001),
and MVD significantly decreased in group B as compared
with group A (P < 0 .001) (Figure 4).
Correlation of perfusion parameters and
histopathological finding
There were positive correlations between tumor cell
density and nPE (r = 0.686, P <0.001), nWiAUC (r =
0.681, P <0.001), nWiR(r = 0.606, P < 0.001), and nWiPI
(r = 0.542, P <0.001). Tumor MVD stained with CD34
Figure 2 Changes of tumor perfusion after treatment with different dose cisplatin. (A) Representative contrast-enhanced ultrasound images of
tumors (arrows) from Group A, Group B and Group C on day 7. (B) Changes of tumor perfusion parameters at the different time points studied. On
days 3, tumor perfusion significantly decreased in group C when compared with group A (* = P < 0.05). On day 7, tumor perfusion significantly
decreased in group B and group C when compared with group A (* = P < 0.05), and further decreased in group C when compared with group
B (* = P < 0.05). Group A, control tumors; Group B, tumors treated with 1 mg/kg cisplatin; Group C, tumors treated with 3 mg/kg cisplatin.
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nWiAUC (r = 0.604, P <0.001), nWiR(r = 0.633, P < 0.001),
and nWiPI (r = 0.602, P <0.001).
Discussion
Multiple strategies for improving the efficacy of chemo-
therapy have been explored by applying novel anti-
tumor agents, different schedules, and new combination
regimens. Given the theory that cells can be killed by
higher doses of chemotherapy drugs but can be resistantto lower doses of the same drug, high-dose chemother-
apy with some promising results became a popular yet
controversial treatment [19]. It has made progress in
treating certain types of tumor, however, which given
serious toxic side effects. Therefore, it is important to
precisely assess the response to different dose of cyto-
toxic therapy, so as to reduce side effects and unneces-
sary costs of ineffective therapy.
In this study, we evaluated the potential utility of dy-
namic contrast-enhanced ultrasound to provide an early
Figure 3 Histopathologic analysis of tumor cell density changes after treatment with different dose cisplatin. (A) Tumor cell density
significantly decreased in groups B and C when compared with group A (* = P < 0.05), and further decreased in group C when compared with
group B (* = P < 0.05). (B) Photomicrographs of HE stained sections of the three groups on days 0, 3, and 7. Scale bars: 50 μm.
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pose, we employed MCF-7 tumor-bearing mice treated
with two different dose of cisplatin (1 mg/kg.d−1, 3 mg/
kg−1, i.p.) as a model system. The activity of cisplatin is
thought to be a result of inter- and intrastrand DNA
cross-links [20]. Therefore, cytostatic concentrations of
cisplatin result in cell arrest in the G1-S or G2-M phase
in vitro, and then cell death [21]. At the cisplatin doses
used in this protocol (1 mg/kg and 3 mg/kg), the tumor
growth was inhibited but was not completely stopped.
Tumor volume of the treated and control tumors were
increased on days 3 and 7 as compared with day 0 and
there were no significant differences among the three
groups until 7 days post treatment, tumor volumes ofgroup B and C were significantly smaller than that of group
A. In contrast, the therapeutic effectiveness of different
doses cisplatin could be assessed by quantifying the tumor
perfusion changes with contrast-enhanced ultrasound:
treatment with higher dose cisplatin resulted in much earl-
ier and more significant reduction in tumor blood perfusion
as compared treatment with lower dose cisplatin. Moreover,
the decrease in blood perfusion of treated tumors on
contrast-enhanced ultrasound was associated with reduc-
tion in tumor cell density and MVD as shown by both
histopathologic and immunochemistry examinations: treat-
ment with higher dose cisplatin resulted in much earlier
and more significant reduction in tumor cell density and
MVD as compared treatment with lower dose cisplatin.
Figure 4 MVD changes after treatment with different dose cisplatin. (A) On days 3 and 7, MVD significantly decreased in group C when
compared with group A and B, and further decreased in group B as compared with group A on day 7 (* = P < 0.05). (B) Photomicrographs of
CD34 stained sections of the three groups on days 0, 3, and 7. Scale bars: 100 μm
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ferent dose of cytotoxic therapy, other imaging strategies
including positron emission tomography (PET) [22],
contrast-enhanced MRI [23] and contrast-enhanced CT
[24], are under evaluation to determine their ability to
classify tumor response to different doses of con-
ventional chemotherapeutic drugs and antiangiogenic
agents. Higher dose of chemotherapy had been associ-
ated with greater decrease in tumor glucose metabolism
[25] or tumor blood perfusion [26]. However, although
dynamic contrast-enhanced MRI offers relatively good
sensitivity and spatial resolution in soft tissue imaging,
the possibility to perform whole organ scans, as well as
functional imaging [27], much of the spatial resolutionmust be sacrificed to get a sufficient frame rate for bolus
tracking in DCE-MRI. Perfusion CT imaging is suitable
for accurate assessment of tissue perfusion because
change in CT image intensity is directly proportional to
concentration of contrast agents [27]. However, the use
of CT for repeated scanning was limited by the high
concentrations of CT contrast agent and the relatively
high doses of radiation. PET is highly sensitive to very
low concentrations of contrast agents and is well suited to
molecular imaging, however, it suffers from poor spatial
resolution [27]. Ultrasound is an easy available technique
for monitoring therapeutic effects and has been frequently
used in clinical practice. Contrast-enhanced ultrasound
imaging offers the major advantages of evaluating tumor
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compared to other imaging modalities used to assess
tumor blood perfusion. In this study, promising results
were found: the vascular response to different dose of
cytotoxic chemotherapy could be determined by using
dynamic contrast-enhanced ultrasound in a mouse breast
cancer model.
Conventional chemotherapeutics do not specifically
target tumor cells, but rather interfere with cell division,
such as by inhibiting enzymes involved in DNA replica-
tion or metabolism (for example, topoisomerases and
thymidylate synthase), or microtubules. Antineoplastic
drugs killing tumor cells follows first-order kinetics: spe-
cific dose kills a specific fraction of tumor cells regard-
less of population. In this study we found that high dose
cisplatin resulted in more significant decrease in tumor
cell density as compared with low dose cisplatin. Differ-
ent fraction of cancer cells’ death could cause different
degree decrease in tumor metabolic activity, which will
correspondingly lead to different degree in the reduction
of tumor blood perfusion. On the other hand, investiga-
tors have demonstrated that most conventional cytotoxic
drugs can exert antiangiogenic effects [28]. Chemothera-
peutics do not specifically target tumor cells, but rather
interfere with cell division, including endothelial cell
division takes place during new blood vessel formation
[29]. So they could cause apoptosis of endothelial cells
in the newly formed tumor microvessels. In this study,
treated with higher dose cisplatin resulted in more sig-
nificant reduction in MVD as compared treated with
lower dose cisplatin and different degree of vascular
disrupture could lead to different degree in the reduc-
tion of tumor perfusion.
There are some limitations in this study. First, a po-
tential limitation of this study was that subcutaneous
tumor xenografts may behave differently compared with
orthotopic or transgenic mouse models, which better re-
flect the microenvironment of human cancers. Second,
it would be of great value if quantification of tumor per-
fusion with contrast-enhanced ultrasound could deter-
mine the highest achievable treatment dose at which a
further increasing the does of chemotherapy does not
produce a further beneficial effect. However, it will be al-
most impossible to determine the highest achievable
treatment dose, especially in an animal study, because
given dose of an antineoplastic compound would destroy
a certain fraction of tumor cells, and the efficiency of
tumor chemotherapy, to a great extent, is dependent on
the dosage of drugs and higher doses are supposed to be
more effective. In this study, treatment with 3 mg/kg cis-
platin resulted in much more significant decreases in
tumor cell density and MVD than 1 mg/kg on the breast
cancer bearing mice, however, the side effect of 3 mg/kg
was much more serious than 1 mg/kg. If treatment withmuch higher dose, it would be questionable whether the
mice could tolerate the treatment to the end of the
study. Moreover, the highest achievable treatment dose
should not be determined by the vascular reponse, but
the relationship between tumor growth reduction and
how well the patients tolerate a given dose. Further stud-
ies are needed to determine the relationships between
tumor vascular response and the longitudinal treatment
outcome. Third, although there were positive correla-
tions between US perfusion parameters and the histo-
pathological findings (cell density and MVD), the
changes in cell density and MVD were more profound
than those in US perfusion parameters, which might due
to that cell density and MVD were measured from the
“hot spots” approach, and US perfusion data was mea-
sured from the tumor of maximum cross section. A
complete quantification of tumor perfusion and histo-
pathological changes throughout the whole tumor
volume could improve the relevance of the US perfusion
parameters with cell density and MVD.
Conclusions
In conclusion, our study suggests that contrast-enhanced
US by quantifying intratumor blood flow can evaluate
tumor vascular response to different dose of chemo-
therapy, which may help to guide drug dosage during
tumor chemotherapy.
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